PFE : BRAFTOVI Combination Shows Improved Response In Phase 3 Trial For Metastatic Colorectal Cancer
Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...